-
公开(公告)号：EP3217870B1
公开(公告)日：2020-01-08
申请号：EP14812340.9
申请日：2014-11-14
-
公开(公告)号：EP2978402B1
公开(公告)日：2019-10-16
申请号：EP14715870.3
申请日：2014-03-27
-
公开(公告)号：EP3402821A1
公开(公告)日：2018-11-21
申请号：EP17701290.3
申请日：2017-01-16
申请人： Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts , Eberhard Karls Universität Tübingen
CPC分类号： C07K16/3069 , C07K16/2809 , C07K16/3084 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/73
摘要： The present invention provides a novel PSMA binding antibody termed 10B3 and pharmaceutical and diagnostic uses of the antibody 10B3. The PSMA antibody 10B3 does not cross-compete with the state of the art PMSA binding antibody J591 and has a reduced induction of antigen shift compared to J591 and a unique reactivity with squamous cell carcinoma (SCC) cells of different origin.
-
公开(公告)号：EP3098305B1
公开(公告)日：2018-10-03
申请号：EP16178934.2
申请日：2008-08-13
发明人： Just, Lothar , Schmidt, Timo , Maser, Franz
IPC分类号： C12N5/00 , C07K14/435 , A61K47/42
CPC分类号： A61K47/42 , C12N5/0068 , C12N2533/54
-
公开(公告)号：EP3057572B1
公开(公告)日：2018-01-31
申请号：EP14777914.4
申请日：2014-09-17
CPC分类号： A61K9/1075 , A61K9/0048 , A61K9/107 , A61K31/557 , A61K31/7036 , A61K47/26 , A61K47/6907
摘要： The invention relates to compositions and methods that utilize polymeric nanoparticles to deliver a therapeutic compound to ocular cells or ocular tissue. Provided is a drug-loaded micelle comprising self-assembled amphiphilic biopolymers, such as hydrophobically modified nucleic acids or polypeptides, for use as ophthalmic drug delivery system. Also provided are ophthalmic compositions and methods for preventing or treating an ophthalmic disease.
-
公开(公告)号：EP2883058B1
公开(公告)日：2018-01-03
申请号：EP13748063.8
申请日：2013-08-13
申请人： Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) , Deutsche Diabetes-Forschungsgesellschaft E.V. - Träger Des Deutschen Diabetes-Zentrums Düsseldorf , Eberhard Karls Universität Tübingen Medizinische Fakultät
发明人： RATHMANN, Wolfgang , HERDER, Christian , ILLIG, Thomas , ADAMSKI, Jerzy , WANG-SATTLER, Rui , YU, Zhongao , WICHMANN, H.-Erich , HÄRING, Hans-Ulrich , PETERS, Annette , MEISINGER, Christine , HRABÉ DE ANGELIS,Martin , RODEN, Michael , MEITINGER, Thomas
CPC分类号： G01N33/487 , G01N24/08 , G01N30/02 , G01N30/72 , G01N30/7206 , G01N33/49 , G01N33/6893 , G01N33/92 , G01N2030/025 , G01N2030/027 , G01N2030/8813 , G01N2500/10 , G01N2800/042 , G01N2800/50
摘要： The present invention relates to a method of identifying a predisposition for developing type 2 diabetes mellitus in a subject, said method comprising the step of assessing in a sample obtained from said subject the amount of one or more metabolite(s) selected from (a) a first group comprising the metabolites glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2, phosphatidylcholine acyl-alkyl C36:3 and isobaric metabolites having the same molecular mass as glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2 or phosphatidylcholine acyl-alkyl C36:3 but different chemical formula; and/or (b) a second group comprising the metabolite acetylcarnitine C2 and an isobaric metabolite having the same molecular weight as acetylcarnitine C2 but different chemical formula; wherein a decrease in the amount of a metabolite selected from said first group or an increase in the amount of a metabolite selected from said second group as compared to the amount of the corresponding metabolite(s) of a control is indicative of a predisposition to develop type 2 diabetes mellitus. Further, the invention relates to a method of identifying a compound capable of preventing type 2 diabetes mellitus and diseases associated therewith or serving as a lead compound for developing a compound capable of preventing type 2 diabetes mellitus and diseases associated therewith and a method of selecting a therapy to prevent type 2 diabetes mellitus. Also, the invention relates to a kit.
-
公开(公告)号：EP3218491A1
公开(公告)日：2017-09-20
申请号：EP15794491.9
申请日：2015-10-29
发明人： AMANN, Ralf , RZIHA, Hans-Joachim
IPC分类号： C12N15/64 , C12N15/90 , G01N33/53 , G01N33/577
CPC分类号： C12N15/64 , A61K39/0011 , A61K39/12 , C07K14/005 , C07K14/70514 , C12N15/1013 , C12N15/907 , C12N2760/20134 , C12N2800/107
摘要： The present invention relates to a method for producing recombinant expression vectors, to a kit adapted for carrying out said method, to a vector used in this method, to a cell containing said vector and to the use of said vector.
摘要翻译： 本发明涉及生产重组表达载体的方法，适于实施该方法的试剂盒，用于该方法的载体，含有该载体的细胞以及该载体的用途。
-
公开(公告)号：EP3174390A1
公开(公告)日：2017-06-07
申请号：EP15745431.5
申请日：2015-07-27
发明人： HIRT, Bernhard , ZEYHER, Claus , GLEISER, Corrina , JUST, Lothar
CPC分类号： C07D207/28 , A01N1/0226 , A01N43/36 , A01N43/48 , A61K8/4913 , A61K8/494 , A61Q19/00 , C07D403/06 , C07D487/10
摘要： The present invention relates to a composition for modulating the activity of non-structural proteins and to a compound contained in said composition.
摘要翻译： 本发明涉及用于调节非结构蛋白质和其中含有的化合物的活性的组合物。
-
29.发明授权PARALLELISIERTE MAJORITY-LOGIC DEKODIERUNG VON REED-MULLER KODES 有权平行的大型LOGO DEKODIERUNG VON REED-MULLER KODES
公开(公告)号：EP2951927B1
公开(公告)日：2017-04-12
申请号：EP14720883.9
申请日：2014-01-24
发明人： BERTRAM, Juliane , HUBER, Michael , HAUCK, Peter
CPC分类号： H03M13/43 , H03M13/136 , H03M13/373 , H03M13/6561 , H03M13/6575
-
公开(公告)号：EP3105316A1
公开(公告)日：2016-12-21
申请号：EP15706193.8
申请日：2015-02-16
IPC分类号： C12N5/077
CPC分类号： C12N5/0654 , A61L2430/02 , C12N5/0656 , C12N7/00 , C12N2501/998 , C12N2510/04 , C12N2710/22022 , C12N2740/15043
摘要： The invention relates to an immortalized cell, a cell line containing said immortalized cell, a cell culture containing the immortalized cell or cell line, and a method for preparing an immortalized cell.
-
-
-
-
-
-
-
-
-
搜索结果
385 条记录 (耗时 0.037 秒)
